Európska únia - slovenčina - EMA (European Medicines Agency)

octapharma ab - simoctocog alfa - hemofília a - krvné faktory koagulácie - liečba a profylaxia krvácania u pacientov s hemofíliou a (vrodená deficiencia faktora viii). nuwiq môžu byť použité pre všetky vekové skupiny.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

cheplapharm arzneimittel gmbh, nemecko - tretinoín - 44 - cytostatica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

glaxosmithkline consumer healthcare czech republic s.r.o., Česká republika - ibuprofén, kombinácie - 07 - analgetica, antipyretica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

krewel meuselbach gmbh, nemecko - iné liečivá proti nachladnutiu - 07 - analgetica, antipyretica

Európska únia - slovenčina - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, hydrochlorid metformín - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Európska únia - slovenčina - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, hydrochlorid metformín - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 a 5. 1 pre dostupné údaje o rôznych kombináciách).

Európska únia - slovenčina - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, hydrochlorid metformín - diabetes mellitus, typ 2 - lieky používané pri cukrovke - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Európska únia - slovenčina - EMA (European Medicines Agency)

novartis europharm limited - lapatinib - neoplazmy prsníkov - protein kinase inhibítory - tyverb je indikovaný na liečbu pacientov s rakovinou prsníka, ktorých nádory overexpress her2 (erbb2):v kombinácii s capecitabine pre pacientov s pokročilým alebo metastatickým ochorením s progresiou nasledujúce pred terapia, ktorá musí obsahovať anthracyclines a taxanes a terapie s trastuzumab v metastatickým nastavenie;v kombinácii s trastuzumab pre pacientov s hormón-receptor-negatívne metastatické ochorenie, ktoré prebiehalo na základe predchádzajúceho trastuzumab terapie resp. terapií v kombinácii s chemoterapiou;v kombinácii s inhibítor aromatázy pre post-menopauzálnych žien s hormón-receptor-pozitívne metastázy, nie sú v súčasnosti určené pre chemoterapia. pacienti v registračné štúdie neboli predtým liečení trastuzumab alebo inhibítor aromatázy. nie sú k dispozícii údaje o účinnosti tejto kombinácie vzhľadom na trastuzumab v kombinácii s inhibítor aromatázy v tejto populácie pacientov.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

angelini pharma Česká republika s.r.o. - leuprorelín - 56 - hormona (lieČiva s hormonÁlnou aktivitou)

Európska únia - slovenčina - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - radionuklidové zobrazovanie - diagnostické rádiofarmaká - tento liek je určený len na diagnostické účely. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.